Here are the latest quarterly results of Dishman Pharma. For more details, see the Dishman Pharma financial fact sheet and Dishman Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Jun-15* |
3
Sep-15* |
3
Dec-15* |
3
Mar-16* |
3
Jun-16* |
3
Sep-16* |
3
Dec-16* |
3
Mar-17* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 4,005 | 3,812 | 3,887 | 4,221 | 3,754 | 4,366 | 3,621 | 5,342 | |
Other income | Rs m | 41 | 76 | 17 | 130 | 70 | 77 | 155 | 38 | |
Turnover | Rs m | 4,047 | 3,888 | 3,904 | 4,351 | 3,824 | 4,442 | 3,776 | 5,380 | |
Expenses | Rs m | 2,961 | 2,897 | 2,787 | 3,175 | 2,732 | 3,208 | 2,664 | 3,875 | |
Gross profit | Rs m | 1,044 | 915 | 1,100 | 1,046 | 1,022 | 1,158 | 953 | 1,462 | |
Depreciation | Rs m | 259 | 261 | 271 | 299 | 285 | 309 | 293 | 570 | |
Interest | Rs m | 319 | 236 | 185 | 205 | 225 | 189 | 134 | 101 | |
Profit before tax | Rs m | 507 | 494 | 661 | 672 | 583 | 736 | 682 | 829 | |
Tax | Rs m | 130 | 129 | 191 | 174 | 127 | 190 | 175 | 401 | |
Profit after tax | Rs m | 378 | 365 | 469 | 498 | 455 | 547 | 507 | 428 | |
Gross profit margin | % | 26.1 | 24.0 | 28.3 | 24.8 | 27.2 | 26.5 | 26.3 | 27.4 | |
Effective tax rate | % | 25.6 | 26.1 | 29.0 | 25.8 | 21.9 | 25.8 | 25.7 | 48.4 | |
Net profit margin | % | 9.4 | 9.6 | 12.1 | 11.8 | 12.1 | 12.5 | 14.0 | 8.0 | |
Diluted EPS | Rs | 2.3 | 2.3 | 2.9 | 3.1 | 2.8 | 3.4 | 3.1 | 2.7 | |
Diluted EPS (TTM) | Rs | 8.3 | 8.5 | 9.9 | 10.6 | 11.1 | 12.2 | 12.4 | 12.0 | |
![]() |
More Pharmaceuticals Company Quarterly Results: CIPLA ASTRAZENECA PHARMA UNICHEM LAB FRESENIUS KABI ONCO. AUROBINDO PHARMA
Compare DISHMAN PHARMA With: CIPLA ASTRAZENECA PHARMA UNICHEM LAB FRESENIUS KABI ONCO. AUROBINDO PHARMA
Compare DISHMAN PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
Ajit Dayal on how India's vaccine strategy will impact the markets.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
In this video I tell you the three Nifty ETFs I think are the best.
There is no stopping this 11-bagger stock from significant upside.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
More